[go: up one dir, main page]

SK21195A3 - Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof - Google Patents

Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof Download PDF

Info

Publication number
SK21195A3
SK21195A3 SK211-95A SK21195A SK21195A3 SK 21195 A3 SK21195 A3 SK 21195A3 SK 21195 A SK21195 A SK 21195A SK 21195 A3 SK21195 A3 SK 21195A3
Authority
SK
Slovakia
Prior art keywords
cells
cell
proliferation
mice
production
Prior art date
Application number
SK211-95A
Other languages
English (en)
Slovak (sk)
Inventor
Robert Coffman
Vries Jan E De
Waal Malefyt R De
Fiona Powrie
Donna Rennick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of SK21195A3 publication Critical patent/SK21195A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/247IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2026IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2066IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
SK211-95A 1992-08-20 1993-08-18 Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof SK21195A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93346292A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
US93341992A 1992-08-21 1992-08-21
PCT/US1993/007646 WO1994004180A2 (en) 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same

Publications (1)

Publication Number Publication Date
SK21195A3 true SK21195A3 (en) 1996-10-02

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
SK211-95A SK21195A3 (en) 1992-08-20 1993-08-18 Pharmaceutical substance containing il-4 and/or il-10 or antibodies against il-4 and il-10, method of manufacture and use thereof

Country Status (23)

Country Link
EP (2) EP0671933B1 (da)
JP (1) JP3494647B2 (da)
KR (1) KR0170037B1 (da)
CN (1) CN1090204A (da)
AT (1) ATE162947T1 (da)
AU (1) AU680628B2 (da)
CA (1) CA2142861C (da)
CZ (1) CZ283488B6 (da)
DE (1) DE69316921T2 (da)
DK (1) DK0671933T3 (da)
ES (1) ES2111769T3 (da)
FI (1) FI950697A (da)
GR (1) GR3026635T3 (da)
HK (1) HK1004326A1 (da)
HU (1) HU220103B (da)
IL (1) IL106725A (da)
MX (1) MX9305054A (da)
MY (1) MY111402A (da)
PL (1) PL307566A1 (da)
RU (1) RU2120802C1 (da)
SK (1) SK21195A3 (da)
TW (1) TW243415B (da)
WO (1) WO1994004180A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
HU220344B (hu) * 1994-07-05 2001-12-28 Steeno Research Group A/S Immunmodulátorok
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
CA2251733A1 (en) * 1996-04-17 1997-10-23 Patrick T. Prendergast Dhea combination therapy
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
WO2000047558A1 (fr) 1999-02-10 2000-08-17 Welfide Corporation Composes amide et leur utilisation medicinale
ES2395991T3 (es) * 1999-12-03 2013-02-18 Baxter International Inc. Ensayo de pirogenicidad para su uso con sistemas de inmunoensayo automáticos
BR0109705A (pt) 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
CN1441675A (zh) 2000-05-12 2003-09-10 贝斯以色列护理医疗中心有限公司 免疫抑制组合物及方法
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
PE20090046A1 (es) * 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
EP1931762B1 (en) * 2005-10-03 2012-12-05 Actogenix N.V. Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
WO2008054585A2 (en) * 2006-09-28 2008-05-08 Schering Corporation Use of pegylated il-10 to treat cancer
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
AU2014254019B2 (en) * 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
EP3021873B8 (en) 2013-07-18 2018-10-24 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DE69201128T2 (de) * 1991-01-16 1995-05-24 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
KR0170037B1 (ko) 1999-02-01
DE69316921T2 (de) 1998-06-04
CA2142861A1 (en) 1994-03-03
HU9500467D0 (en) 1995-04-28
FI950697A0 (fi) 1995-02-16
MY111402A (en) 2000-04-29
HUT70976A (en) 1995-11-28
MX9305054A (es) 1994-02-28
HU220103B (hu) 2001-10-28
ATE162947T1 (de) 1998-02-15
IL106725A (en) 2000-12-06
EP0671933A1 (en) 1995-09-20
FI950697A (fi) 1995-04-07
CZ283488B6 (cs) 1998-04-15
RU95108330A (ru) 1996-11-27
KR950702841A (ko) 1995-08-23
DK0671933T3 (da) 1998-09-23
RU2120802C1 (ru) 1998-10-27
ES2111769T3 (es) 1998-03-16
EP0801951A2 (en) 1997-10-22
AU680628B2 (en) 1997-08-07
CN1090204A (zh) 1994-08-03
TW243415B (da) 1995-03-21
CZ44195A3 (en) 1995-10-18
WO1994004180A2 (en) 1994-03-03
JPH08500362A (ja) 1996-01-16
DE69316921D1 (de) 1998-03-12
AU5010893A (en) 1994-03-15
PL307566A1 (en) 1995-05-29
WO1994004180A3 (en) 1994-06-09
HK1004326A1 (en) 1998-11-20
GR3026635T3 (en) 1998-07-31
EP0671933B1 (en) 1998-02-04
IL106725A0 (en) 1993-12-08
CA2142861C (en) 2000-08-15
EP0801951A3 (en) 1998-05-20
JP3494647B2 (ja) 2004-02-09

Similar Documents

Publication Publication Date Title
AU680628B2 (en) Novel uses of IL-4 and/or IL-10, and antibodies against the same
Blazar et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
Grabstein et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody.
RU2280255C2 (ru) Модуляция il-2- и il-15-опосредованных т-клеточных ответов
US7198789B2 (en) Methods and compositions for modulating interleukin-21 receptor activity
US8637011B2 (en) Modulation of NKG2D
CN1441675A (zh) 免疫抑制组合物及方法
KR20070095949A (ko) 자가면역 장애의 치료 방법
KR20010042364A (ko) 성숙 FLINT(mFLINT) 폴리펩타이드 또는 TNF수용체인 OPG3의 치료학적 용도
KR20010013964A (ko) 치료용 단백질 저해제 증후군에 대한 cd154 차단 요법
KR20190066067A (ko) 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
KR100271197B1 (ko) 인터루킨-10동족체또는길항제를포함하는내독소-또는초항원유도된독성치료용의약제학적조성물
EP1653977A2 (en) Treatment of disorders associated with natural killer t cells
Smyth et al. Adoptive transfer: the role of perforin in mouse cytotoxic T lymphocyte rejection of human tumor xenografts in vivo
NZ255757A (en) Compositions and methods for the use of il-4 and/or il-10 and antibodies against these cytokines
JPH11510806A (ja) 免疫抑制治療のためのインターロイキン10およびシクロスポリンの併用
RU2233881C2 (ru) Средства и способ получения гемопоэтического белка
Dean et al. Pre-clinical toxicity of IL-4: A model for studying protein therapeutics
WO2008014035A2 (en) Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
Frasca et al. Activation of gp130 signaling in vivo by the IL‐6 super‐agonist K‐7/D‐6 accelerates repopulation of lymphoid organs after irradiation
Grabstein Inhibition of Murine B and T Lymphopoiesis In Vivo by an Anti-Interleukln 7 Monoclonal Antibody By Kenneth H. Grabstein, Thomas J. Waldschmidt,* Fred D. Finkelman,~ Bruce W. Hess, Alan R. Alpert, Norman E. Boiani, Anthony E. Namen, and Philip J. Morrissey
Yang et al. Human Interleukin-15 Improves
Delayed-Type Targeting the IL-15 Receptor with an
Ingram Identification and characterization of a unique subpopulation of double negative splenic T cells which express the [alpha beta] T cell receptor
Cardiac Selective Blockade of IL-15 by Soluble IL-15